176 related articles for article (PubMed ID: 33984805)
41. [Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
Ercilla Liceaga M; Andueza Granados K; Fernández González I; Barcia Romero MJ
Farm Hosp; 2003; 27(2):93-100. PubMed ID: 12717564
[TBL] [Abstract][Full Text] [Related]
42. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
[TBL] [Abstract][Full Text] [Related]
43. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD
Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204
[TBL] [Abstract][Full Text] [Related]
44. Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide.
Zhang Z; Chen Y; Meng H; Sui M; Zhou Q; Shi C; Han L; Wang H; Zhou J
Leuk Lymphoma; 2013 Sep; 54(9):2041-6. PubMed ID: 23343178
[TBL] [Abstract][Full Text] [Related]
45. Curing APL through PML/RARA degradation by As2O3.
Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
[TBL] [Abstract][Full Text] [Related]
46. Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
Powell BL
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1317-9. PubMed ID: 21929304
[No Abstract] [Full Text] [Related]
47. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
48. Arsenic: a new place?
Vincent PC
Pathology; 1999 May; 31(2):81-2. PubMed ID: 10399159
[No Abstract] [Full Text] [Related]
49. How to manage acute promyelocytic leukemia.
Mi JQ; Li JM; Shen ZX; Chen SJ; Chen Z
Leukemia; 2012 Aug; 26(8):1743-51. PubMed ID: 22422168
[TBL] [Abstract][Full Text] [Related]
50. Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.
Au WY; Lang BH; Fong BM; Mao KJ; Tam S
Leuk Lymphoma; 2014 May; 55(5):1184-5. PubMed ID: 23964647
[No Abstract] [Full Text] [Related]
51. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
[TBL] [Abstract][Full Text] [Related]
52. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
Muto A; Kizaki M; Kawamura C; Matsushita H; Fukuchi Y; Umezawa A; Yamada T; Hata J; Hozumi N; Yamato K; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2001 Aug; 15(8):1176-84. PubMed ID: 11480559
[TBL] [Abstract][Full Text] [Related]
53. Scientists explore use of arsenic in therapy.
Miller M
J Natl Cancer Inst; 1998 Dec; 90(24):1866-7. PubMed ID: 9862622
[No Abstract] [Full Text] [Related]
54. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
55. Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series.
Gupta S; Bagel B; Gujral S; Subramanian PG; Khattry N; Menon H; Nair R
Leuk Lymphoma; 2012 Nov; 53(11):2192-4. PubMed ID: 22452590
[TBL] [Abstract][Full Text] [Related]
56. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin F; Roncolato F; Ho WK
Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
[TBL] [Abstract][Full Text] [Related]
57. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
Zhang Y; Zhang Z; Li J; Li L; Han X; Han L; Hu L; Wang S; Zhao Y; Li X; Zhang Y; Fan S; Lv C; Li Y; Su Y; Zhao H; Zhang X; Zhou J
Cancer; 2013 Jan; 119(1):115-25. PubMed ID: 22930197
[TBL] [Abstract][Full Text] [Related]
58. [Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
Haanen C; Vermes I
Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1738-41. PubMed ID: 10494320
[TBL] [Abstract][Full Text] [Related]
59. Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
Vassilakopoulos TP; Asimakopoulos JV; Plata E; Kelepesis G; Petevi K; Koutsi C; Papageorgiou L; Tsaftaridis P; Angelopoulou MK; Konstantopoulos K; Meletis J
Leuk Lymphoma; 2017 Jul; 58(7):1743-1746. PubMed ID: 27919176
[No Abstract] [Full Text] [Related]
60. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions.
Lengfelder E; Hofmann WK; Nowak D
Expert Rev Anticancer Ther; 2013 Sep; 13(9):1035-43. PubMed ID: 24053202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
